The CAR-PRISM phase II single-arm trial presented at AACR 2026 reported that a single infusion of ciltacabtagene autoleucel (Carvykti) produced 100% minimal residual disease (MRD) negativity in 20 patients with high-risk smoldering multiple myeloma (SMM). While the MedicalXpress coverage accurately relayed presenter Omar Nadeem’s comments on shifting from watchful waiting to early interception, it underplayed critical limitations and broader context. This was a small, non-randomized study (n=20) without a control arm, making it impossible to definitively attribute long-term prevention benefit versus the natural history of high-risk SMM, where roughly 50% progress within two years per the 20/2/20 criteria. Peer-reviewed publication is still pending; thus the data remain conference-level evidence with potential industry bias given Janssen’s sponsorship of both the trial and the commercial product.

Original reporting also gave insufficient weight to the November 2025 FDA approval of subcutaneous daratumumab for high-risk SMM based on a larger randomized phase 3 trial (approximately 390 patients) that demonstrated a 51% reduction in progression risk. That trial, however, required up to three years of repeated dosing and did not use MRD negativity as a primary endpoint, leaving open whether deeper immunologic resets are possible. CAR-PRISM’s hypothesis that “fitter” autologous T cells in the earlier disease state will yield superior expansion and persistence is mechanistically plausible and aligns with patterns seen in CARTITUDE-1 (phase 1b/2, n=97 relapsed/refractory patients) where BCMA CAR-T produced deep responses but carried grade 3+ cytokine release syndrome and neurotoxicity risks. Applying the same therapy to asymptomatic individuals raises the stakes: overtreatment of patients who might never progress must be balanced against preventing irreversible organ damage.

Synthesizing these datasets reveals an under-appreciated shift in immuno-oncology. Just as anti-PD-1 agents moved from metastatic to adjuvant and now neoadjuvant settings, BCMA CAR-T is testing the pre-malignant niche. The therapeutic appeal is obvious—one-time infusion versus chronic monoclonal antibody therapy—but CAR-PRISM did not fully report long-term CAR-T persistence, B-cell aplasia duration, or infection rates, all of which proved clinically meaningful in later-line use. Economic modeling also favors a potential one-and-done paradigm if durable remissions exceed three years, yet current U.S. CAR-T manufacturing and hospitalization costs remain barriers to widespread frontline adoption.

What most coverage missed is the immunologic window: smoldering disease carries lower tumor burden and less T-cell exhaustion, potentially improving the therapeutic index. Still, exposing otherwise healthy individuals to lymphodepletion and possible prolonged cytopenias demands rigorous risk-benefit data from upcoming randomized trials. If sustained MRD negativity translates into reduced progression without quality-of-life erosion, this approach could close a genuine gap in proactive immuno-oncology, moving the field from reactive symptom management to true cancer interception. Larger phase 3 studies with MRD endpoints, quality-of-life metrics, and five-year follow-up are now essential before practice-changing recommendations can be made.